We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Multinational Haemapheresis Vigilance Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01576237
Recruitment Status : Active, not recruiting
First Posted : April 12, 2012
Last Update Posted : July 22, 2021
Aix Scientifics
Information provided by (Responsible Party):
DGTI - Haemapheresis Vigilance Working Party

Brief Summary:
During a seven years period the participating transfusion medicine establishments will report all their non-trivial adverse events (AE) occurring during preparative hemaphereses. Complications may be related to the blood donors, the blood products, the disposables or the apheresis devices. The study hypothesis regarding each participating center is that their procedure-related AE rate is not higher than the respective rate of all other centers in total.

Condition or disease Intervention/treatment
Blood Donation With Hemapheresis Other: blood donation

Detailed Description:
In the scope of this study the participating transfusion medicine establishments obligate themselves to record all significant Adverse Events (AE) related to preparative hemaphereses of healthy donors. All complications (phlebotomy and circulation problems, citrate toxicity, donor compliance, and technical complications) shall be assessed with respect to plasma-, platelet-, leukocyte- (stem cells, granulocytes, monocytes), and red cell aphereses as well as multicomponent aphereses. Study data are recorded by means of an Internet-based hemapheresis vigilance system. Study results will be evaluated according to the advanced standards of the International Haemovigilance Network (IHN). The study contributes to the quality assurance of each single center as it enables the comparison to other transfusion medicine establishments.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Open Prospective Multi-national Long-term Study to Register Adverse Events Related to Hemaphereses by Means of an Internet-based Haemapheresis Vigilance Questionnaire
Actual Study Start Date : February 2012
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Group/Cohort Intervention/treatment
healthy apheresis donors
healthy blood donors for blood cell aphereses
Other: blood donation
blood donation with preparative hemapheresis

Primary Outcome Measures :
  1. Assessment of all non-trivial adverse events (AE) occurring during hemapheresis [ Time Frame: up to one year ]
    All non-trivial AEs will be recorded regardless of whether anticipated products have been collected or not

Secondary Outcome Measures :
  1. Rate of products per apheresis [ Time Frame: hemapheresis stay: expected time range from 1 hour for plasmaphereses to 5 hours for stem cell aphereses ]
    amount of obtained products vs. anticipated products

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
all blood donors having an Adverse Event during preparative cell aphereses

Inclusion Criteria:

  • blood donor standard criteria :
  • healthy donor of > 50 kg
  • hemoglobin 125 g/L or 7.8 mmol/L (female donors)
  • hemoglobin 135 g/L or 8.4 mmol/L (male donors)
  • hemoglobin > 140 g/L for 2 unit red cell apheresis
  • total proteins >= 60 g/L for plasmapheresis
  • platelet count >= 150 × 10e9/L for platelet apheresis
  • blood volume of > 5 L for 2 unit red cell apheresis
  • normal leukocyte count

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01576237

Sponsors and Collaborators
DGTI - Haemapheresis Vigilance Working Party
Aix Scientifics
Layout table for investigator information
Principal Investigator: Hans-Gert Heuft, PD. Dr. med. Hannover Medical School (MHH)
Additional Information:
Layout table for additonal information
Responsible Party: DGTI - Haemapheresis Vigilance Working Party
ClinicalTrials.gov Identifier: NCT01576237    
Other Study ID Numbers: DGTI-AGHV_01
First Posted: April 12, 2012    Key Record Dates
Last Update Posted: July 22, 2021
Last Verified: July 2021
Keywords provided by DGTI - Haemapheresis Vigilance Working Party:
donor vigilance
platelet apheresis
stem cell apheresis
granulocyte apheresis
monocyte apheresis
red cell apheresis